Scientists at the Vaccine Research Center of the NIH National Institute of Allergy and Infectious Diseases are evaluating a second version of a “universal” influenza vaccine currently termed FluMos-v2.  The product comprises influenza virus hemagglutinin assembled in repeating patterns on a nanoparticle scaffold.  The fragments of virus simulate the immune system to respond to exposure to a viable virus.  The latest version of the candidate vaccine incorporates viral protein from six strains including four influenza A and two influenza B viruses to provide broad protection.

The latest clinical trial will enroll 24 volunteers aged 18 to 50 years.  Two intramuscular injections will be administered 16 weeks apart and subjects will be monitored for safety and response to the vaccine in comparison to 12 recipients of a placebo.

Dr. Hugh Auchincloss, Acting Director of NIAID, stated, “An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.  With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal.”

The technology developed by NIAID could be applied to H5 AND H7 avian influenza viruses to develop an effective vaccine for administration in ovo that ultimately could provide protection for flocks in areas where avian influenza is likely to reoccur.